AstraZeneca Results Presentation Deck
Financial priorities
Q1 2021 results underpinned the strategic journey
Deleveraging/dividend growth
As cash flow improves,
deleveraging and progressive
dividend policy
●
Unchanged priorities for capital
allocation.
Cash-flow growth
28% growth in reported EBITDA
and continued improvement in
working capital management
●
• 2021: anticipate further
improvement in cash flow, cash-
flow metrics and dividend cover
Changes at CER except last four quarters (used for EBITDA).
23
●
Revenue growth
+7%
growth in total revenue in
Q1 2021 excluding the pan-
demic COVID-19 vaccine
Operating leverage
57% ratio of core operating
expenses to total revenue (stable)
●
• 34% growth in core operating
profit
• 34% core operating profit margin
including contribution from 001
BView entire presentation